CCDC6
ENSG00000108091
Target class
Unclassified protein
Chromosome
10
Approved drugs
2
Clinical candidates (approved and in development)
2
- Approved drugs
- 2
- Clinical candidates (approved and in development)
- 2
- Chemical probe available
- No
- Target name
- CCDC6
- Gene name
- Coiled-coil domain containing 6
- Gene symbol
- CCDC6
- Protein name
- Coiled-coil domain-containing protein 6 (Papillary thyroid carcinoma-encoded protein) (Protein H4)
- PTC
- TPC
- H4
- PTC1
- TST1
- D10S170
- Gene biotype
- Protein coding
- Target class
- Unclassified protein
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 57.82
- Tissue specificity (Gini)
- 0.284
- Tissue specificity (tau)
- 0.544
- KEGG gene identifiers
- hsa:8030
- Protein interaction confidence
- 0.8305
- Protein interaction partners
- 14
- End position
- 59907029
- Start position
- 59788747
- Chromosome
- 10
- Strand
- Reverse
- Cytoplasm. Cytoplasm, cytoskeleton . Note=May be a cytoskeletal protein.
- Cytosol
- Tissue specificity (tau)
- 0.543975
- Expression inequality (Gini)
- 0.284486
Expression in transcripts per million
- Artery - Tibial
- 57.82
- Artery - Aorta
- 56.61
- Uterus
- 55.15
- Esophagus - Mucosa
- 51.05
- Vagina
- 49.91
Expression in transcripts per million
- Artery - Tibial57.82
- Artery - Aorta56.61
- Uterus55.15
- Esophagus - Mucosa51.05
- Vagina49.91
- Skin - Sun Exposed (Lower leg)49.16
- Colon - Sigmoid47.15
- Skin - Not Sun Exposed (Suprapubic)45.57
- Cervix - Ectocervix43.05
- Minor Salivary Gland39.49
- Artery - Coronary38.86
- Cervix - Endocervix36.7
- Esophagus - Muscularis35.29
- Cells - Cultured fibroblasts35.02
- Bladder34.91
- Fallopian Tube33.57
- Brain - Nucleus accumbens (basal ganglia)31.94
- Prostate31.81
- Thyroid30.78
- Lung30.24
- Cells - EBV-transformed lymphocytes29.98
- Esophagus - Gastroesophageal Junction28.64
- Brain - Frontal Cortex (BA9)28.41
- Breast - Mammary Tissue26.53
- Colon - Transverse26.12
And 29 more, listed on the interactive page.
Cellular components
- GO:0005829
- GO:0005200
- GO:0005515
- GO:0042802
Related records
Trials (60)
- A Drug Drug Interaction (DDI) Study of Selpercatinib (LY3527723) and Rosuvastatin in Healthy Participants
- A Drug Drug Interaction (DDI) Study of Selpercatinib and Dabigatran in Healthy Participants
- A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLC
- A Relative Bioavailability Study of Selpercatinib (LY3527723) in Healthy Participants
- A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer
- A Study Comparing Two Formulations of Selpercatinib (LY3527723) in Healthy Participants
- A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response
- A Study of Absorption, Metabolism, Excretion, and Absolute Bioavailability of Carbon-14-Labelled [14C] Selpercatinib (LY3527723) in Healthy Male Participants
- A Study of Effect of Food and a Proton Pump Inhibitor on Selpercatinib (LY3527723) in Healthy Participants
- A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal Function
- A Study of Effect of Selpercatinib (LY3527723) on Corrected QT (QTc) Interval in Healthy Participants
- A Study of Effects of Itraconazole and Rifampin on Selpercatinib (LY3527723) in Healthy Participants
- A Study of Effects of Selpercatinib (LY3527723) on Midazolam in Healthy Participants
- A Study of Effects of Selpercatinib (LY3527723) on Repaglinide in Healthy Participants
- A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants
- A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
- A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
- A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).
- A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
- A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
Drugs (2)
- Pralsetinib Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor
- Selpercatinib Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor